Jackson D M, Westlind-Danielsson A
Department of Behavioural, Pharmacology, Astra Arcus AB, Södertälje, Sweden.
Pharmacol Ther. 1994;64(2):291-370. doi: 10.1016/0163-7258(94)90041-8.
The description of new dopamine (DA) receptor subtypes, D1-(D1 and D5) and D2-like (D2A, D2B, D3, D4), has given an impetus to DA research. While selective agonists and antagonists are not generally available yet, the receptor distribution in the brain suggests that they could be new targets for drug development. Binding characteristics and second messenger coupling has been explored in cell lines expressing the new cloned receptors. The absence of selective ligands has meant that in vivo studies have lagged behind. However, progress has been made in understanding the function of DA-containing discrete brain nuclei and the functional consequence of the DA's interaction with other neurotransmitters. This review explores some of the latest advances in these various areas.
新的多巴胺（DA）受体亚型，即D1-型（D1和D5）以及D2-样型（D2A、D2B、D3、D4）的发现推动了多巴胺研究。虽然目前普遍还没有选择性激动剂和拮抗剂，但大脑中的受体分布表明它们可能成为药物研发的新靶点。人们已经在表达新克隆受体的细胞系中探索了其结合特性和第二信使偶联。缺乏选择性配体意味着体内研究滞后。然而，在理解含多巴胺的离散脑核的功能以及多巴胺与其他神经递质相互作用的功能后果方面已经取得了进展。本综述探讨了这些不同领域的一些最新进展。
